NDA 22433/S-006

SUPPLEMENT APPROVAL

AstraZeneca LP
ATTENTION: Pat Patterson
Director, Regulatory Affairs
1800 Concord Pike
P.O. Box 8355
Wilmington, DE 19803

Dear Ms. Patterson:

Please refer to your Supplemental New Drug Application (sNDA) dated July 24, 2012, received July 24, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Brilinta (ticagrelor) 90 mg Tablets.

We acknowledge receipt of your amendment dated January 24, 2013 and your risk evaluation and mitigation strategy (REMS) assessment dated August 14, 2012.

This Prior Approval supplemental new drug application provides for labeling changes to describe a new contraindication for hypersensitivity, new stability information, and a proposed modification to the approved Brilinta (ticagrelor) REMS.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text. These changes are as follows:

FULL PRESCRIBING INFORMATION (FPI) CHANGES

- A new subsection was added to section 4, CONTRAINDICATIONS:

  “4.4 Hypersensitivity
  BRILINTA is contraindicated in patients with hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product [see Adverse Reactions (6.2)].”

- Subsection 6.2, Postmarketing Experience, of ADVERSE REACTIONS was added to read as follows:

  “6.2 Postmarketing Experience
  The following adverse reactions have been identified during post-approval use of BRILINTA. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  Immune system disorders – Hypersensitivity reactions including angioedema [see Contraindications (4.4)].”
In Section 16, HOW SUPPLIED, Storage and Handling, The following language was removed:

“Keep BRILINTA in the container it comes in

Keep BRILINTA tablets dry”

MEDICATION GUIDE CHANGES

Because of the new contraindication, under the section, Who should not take Brilinta?, the following bullet was added:

“are allergic to ticagrelor or any of the ingredients in BRILINTA. See the end of this Medication Guide for a list of ingredients in BRILINTA.”

To eliminate repetitive statements in the Medication Guide, the following section under Who should not take Brilinta? was deleted:

“When instructed by your doctor, you should stop taking BRILINTA 5 days before you have elective surgery. This will help to decrease your risk of bleeding with your surgery or procedure. Your doctor should tell you when to start taking BRILINTA again, as soon as possible after surgery.”

There were also a few minor editorial changes made to throughout the Medication Guide.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert & Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.
RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

The REMS for Brilinta (ticagrelor) was originally approved on July 20, 2011. The REMS consists of a Medication Guide, communication plan, and a timetable for submission of assessments of the REMS. Your proposed modifications to the REMS consist of a revised Medication Guide to include information about the new contraindication for patients with hypersensitivity to Brilinta (ticagrelor) and a revised distribution plan for the Dear Healthcare Provider letter (communication plan) and Medication Guide.

Your proposed modified REMS, submitted July 24, 2012 and appended to this letter, is approved.

The timetable for submission of assessments of the REMS will remain the same as that approved on July 20, 2011. There are no changes to the REMS assessment plan described in our July 20, 2011 letter.

In addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of the FDCA.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

**NDA 22433 REMS CORRESPONDENCE**
(insert concise description of content in bold capital letters, e.g.,
**UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT METHODOLOGY**

An authorized generic drug under this NDA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an authorized generic drug under this NDA, contact us to discuss what will be required in the authorized generic drug REMS submission.

Prominently identify the submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**NDA 22433 REMS ASSESSMENT**

**NEW SUPPLEMENT FOR NDA 22433**
**PROPOSED REMS MODIFICATION**

**NEW SUPPLEMENT (NEW INDICATION FOR USE)**
**FOR NDA 22433**
**REMS ASSESSMENT**
**PROPOSED REMS MODIFICATION (if included)**
If you do not submit electronically, please send 5 copies of REMS-related submissions.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [http://www.fda.gov/opacom/morechoices/fdaforms/cder.html](http://www.fda.gov/opacom/morechoices/fdaforms/cder.html); instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm).

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact:

Alison Blaus, RAC  
Regulatory Project Manager  
(301) 796-1138

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, Pharm.D.  
Deputy Director for Safety  
Division of Cardiovascular and Renal Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURES:  
Content of Labeling  
REMS
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
01/24/2013